Bloom Energy (BE) Is Down 11.2% After Brookfield Expands AI Power Financing To $25 Billion – Has The Bull Case Changed?

BLOOM ENERGY CORP

BLOOM ENERGY CORP

BE

0.00

  • In late June 2026, Bloom Energy and Brookfield expanded their partnership, lifting Brookfield’s financing framework for AI power projects from US$5.00 billion to US$25.00 billion under Brookfield’s AI Infrastructure Fund to support global deployment of Bloom’s onsite fuel cell systems.
  • The fivefold increase in available funding positions Bloom Energy as a key power provider for hyperscaler-grade AI “factories,” where power, compute, and data center infrastructure are planned and financed as a single integrated package.
  • We’ll now examine how Brookfield’s US$25.00 billion financing framework for Bloom’s AI-focused fuel cells could reshape the company’s investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.

Bloom Energy Investment Narrative Recap

To own Bloom Energy today, you have to believe that onsite fuel cells can remain a central solution for AI data center power despite competing clean-energy options and regulatory scrutiny of natural-gas-based systems. The Brookfield expansion meaningfully reinforces the near term AI power catalyst by adding US$25.00 billion of financing capacity, but it also sharpens the key risk that Bloom must execute on rapid, profitable deployment while avoiding overbuilding manufacturing capacity if demand timing shifts.

Among recent developments, Bloom’s move into the Russell 1000 and Russell Top 200 indexes is especially relevant, as it coincides with the Brookfield announcement and Bloom’s surge as an AI power proxy. These index additions can increase visibility and mechanical demand from funds, amplifying the impact of AI-related news on the share price while also potentially heightening volatility if sentiment toward high-growth, premium-valued names cools.

Yet behind the Brookfield funding headlines, investors should still weigh how exposed Bloom remains to natural gas pricing and future carbon policy...

Bloom Energy's narrative projects $10.2 billion revenue and $2.2 billion earnings by 2029. This requires 60.7% yearly revenue growth and roughly a $2.2 billion earnings increase from $6.0 million today.

Uncover how Bloom Energy's forecasts yield a $263.65 fair value, a 9% downside to its current price.

Exploring Other Perspectives

BE 1-Year Stock Price Chart
BE 1-Year Stock Price Chart

Some of the most optimistic analysts already expected Bloom’s revenue to reach about US$17.0 billion and earnings US$5.5 billion by 2029, so this Brookfield news could either reinforce that bullish view or make it look conservative, depending on how you judge the AI power opportunity and the risk that faster renewable adoption squeezes gas based fuel cells.

Explore 6 other fair value estimates on Bloom Energy - why the stock might be worth less than half the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

  • A great starting point for your Bloom Energy research is our analysis highlighting 3 key rewards and 4 important warning signs that could impact your investment decision.
  • Our free Bloom Energy research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bloom Energy's overall financial health at a glance.

Want Some Alternatives?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

  • Outshine the giants: these 15 early-stage AI stocks could fund your retirement.
  • Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
  • AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.